AlphaMadera's AlphaVal page computes TrueBlue, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag TBI as undervalued, fairly valued, or overvalued.

What is TrueBlue, Inc.'s fair value?

Fair value for TBI is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value TBI?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from TBI's most recent reported fundamentals.

TBI - TrueBlue, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $5.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: TBI revenue per share ($53) is 7x the stock price ($8.11). Financials likely reported in a foreign currency.